The US Food and Drug Administration is allowing onto the market the first new hepatitis B vaccine in more than 25 years with the approval of Dynavax’ Heplisav-B.
Vectura has signed an exclusive global agreement with Dynavax Technologies allowing use of its proprietary smart nebuliser technology to deliver an investigational immunotherapeutic to lung cancer patients.